TAP Funding Leads to $1.6 million SBIR Investment from NIH

Knudra Transgenics is proud to announce it is the recipient of a FastTrack SBIR Award. A total of $1.6 million is provided by the National Institutes of Health to develop and optimize Knudra’s RecombiREAD reagent for zebrafish transgenesis. Critical in getting the SBIR investment, a USTAR funded TAP project provided the key preliminary data in C. elegans demonstrating RecombiREAD allows discovery of rare gene-edited animals in large populations.

SBIR STTR America's seed Fund

In the newly funded work, Knudra will adapt the RecombiREAD reporter to become functional in vertebrates. The zebrafish model organism is the chosen vertebrate for study because it provides an easy-to-use embryo for optimizing RecombiREAD discovery. In the age of democratization of genome editing with new tools such as the CRISPR/Cas9 system, there is now a growing screening burden in finding animals that contain the changes desired in their genomes. RecombiREAD holds promise as the tool with the potential to reduce the post-microinjection screening effort by as much as 300 fold. As a result, discovery of biallelic gene insertions becomes much more likely at the downstream step of tissue biopsy verification. Users of RecombiREAD will get immense saving in their transgenesis projects because they will obtain a dramatic reduction in expensive animal husbandry.

Statements in this press release blog post are Forward Looking. Funding activities reported are supported by Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health under award number R44HD090831. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.